Compare Stocks: PRME, BEAM, CRSP, and VRDN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.48 +1.0%	$26.81	$20.23 ▼ $38.26	$2.53B	2.22	2.06 million shs	1.14 million shs
CRSP CRISPR Therapeutics	$55.94 +3.4%	$53.90	$44.12 ▼ $78.48	$5.42B	1.76	1.75 million shs	1.08 million shs
PRME Prime Medicine	$3.08 +6.8%	$3.24	$2.67 ▼ $6.94	$557.74M	2.34	2.94 million shs	2.78 million shs
VRDN Viridian Therapeutics	$19.92 -3.1%	$21.99	$13.18 ▼ $34.29	$2.26B	0.97	2.10 million shs	761,502 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.16%	-4.08%	-17.36%	-29.40%	+5.49%
CRSP CRISPR Therapeutics	-0.26%	-7.27%	-6.29%	-0.91%	-12.29%
PRME Prime Medicine	-0.69%	-9.72%	-20.22%	-21.95%	-43.75%
VRDN Viridian Therapeutics	+0.49%	-4.77%	-10.88%	+11.98%	+1.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.48 +1.0%	$26.81	$20.23 ▼ $38.26	$2.53B	2.22	2.06 million shs	1.14 million shs
CRSP CRISPR Therapeutics	$55.94 +3.4%	$53.90	$44.12 ▼ $78.48	$5.42B	1.76	1.75 million shs	1.08 million shs
PRME Prime Medicine	$3.08 +6.8%	$3.24	$2.67 ▼ $6.94	$557.74M	2.34	2.94 million shs	2.78 million shs
VRDN Viridian Therapeutics	$19.92 -3.1%	$21.99	$13.18 ▼ $34.29	$2.26B	0.97	2.10 million shs	761,502 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.16%	-4.08%	-17.36%	-29.40%	+5.49%
CRSP CRISPR Therapeutics	-0.26%	-7.27%	-6.29%	-0.91%	-12.29%
PRME Prime Medicine	-0.69%	-9.72%	-20.22%	-21.95%	-43.75%
VRDN Viridian Therapeutics	+0.49%	-4.77%	-10.88%	+11.98%	+1.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	100.20% Upside
CRSP CRISPR Therapeutics	2.67	Moderate Buy	$67.94	21.46% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	143.00% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.69	94.20% Upside

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and VRDN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	PRME Prime Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/14/2026	VRDN Viridian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	18.09	N/A	N/A	$12.20 per share	2.01
CRSP CRISPR Therapeutics	$3.51M	1,540.95	N/A	N/A	$20.17 per share	2.77
PRME Prime Medicine	$4.63M	120.46	N/A	N/A	$0.67 per share	4.59
VRDN Viridian Therapeutics	$70.85M	31.86	N/A	N/A	$6.18 per share	3.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest PRME, BEAM, CRSP, and VRDN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CRSP CRISPR Therapeutics	0.34	17.85	17.85
PRME Prime Medicine	N/A	3.05	3.05
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
PRME Prime Medicine	70.37%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CRSP CRISPR Therapeutics	5.20%
PRME Prime Medicine	16.04%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
PRME Prime Medicine	146	181.38 million	152.28 million	N/A
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

PRME, BEAM, CRSP, and VRDN Headlines

Recent News About These Companies

Viridian Therapeutics (NASDAQ:VRDN) Upgraded to Sell at Wall Street Zen

September 26 at 1:24 AM | americanbankingnews.com

Wall Street Zen Upgrades Viridian Therapeutics (NASDAQ:VRDN) to "Sell"

September 26 at 1:23 AM | marketbeat.com

Bank of America Corp DE Makes New $17.35 Million Investment in Viridian Therapeutics, Inc. $VRDN

September 25, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)

September 23, 2026 | theglobeandmail.com

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

September 22, 2026 | finance.yahoo.com

Viridian Therapeutics: Two Products, One Commercial Buildout

September 17, 2026 | seekingalpha.com

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13, 2026 | marketbeat.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8, 2026 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and VRDN Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.48 +0.25 (+1.01%)

As of 03:45 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$55.94 +1.85 (+3.42%)

As of 03:45 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Prime Medicine NASDAQ:PRME

$3.08 +0.20 (+6.77%)

As of 03:45 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Viridian Therapeutics NASDAQ:VRDN

$19.92 -0.65 (-3.14%)

As of 03:45 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, CRSP, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, CRSP, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and VRDN Company Descriptions

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Prime Medicine NASDAQ:PRME

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and VRDN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, CRSP, and VRDN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, CRSP, and VRDN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and VRDN Company Descriptions

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Prime Medicine NASDAQ:PRME

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools